Unicycive Therapeutics Stock Forecast

Stock Price Forecast

According to 10 analysts polled by S&P Global, Unicycive Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $28.4. The average 1-year stock price forecast is 691.09% higher than the current stock price, while the lowest is $13 (+262.12%) and the highest is $42 (+1,069.92%).

Price Target: $28.4 (+691.09%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$13	$28.4	$27.5	$42
Change	+262.12%	+691.09%	+666.02%	+1069.9%

Analyst Ratings

The average analyst rating for Unicycive Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Apr '26	May '26	Jun '26	Jul '26	Aug '26	Sep '26
Strong Buy	7	8	8	8	8	8
Buy	2	2	2	2	2	2
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	9	10	10	10	10	10

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Swayampakula Ramakanth H.C. Wainwright	H.C. Wainwright	Buy Reiterates $13	Buy	Reiterates	$13	+262.12%	Sep 29, 2026
Bruce Jackson StoneX	StoneX	Buy Maintains $13 → $15	Buy	Maintains	$13 → $15	+317.83%	Aug 20, 2026
Jason McCarthy Maxim Group	Maxim Group	Buy Maintains $30	Buy	Maintains	$30	+735.65%	Aug 18, 2026
Mayank Mamtani B. Riley Securities	B. Riley Securities	Buy Maintains $22 → $20	Buy	Maintains	$22 → $20	+457.10%	Aug 13, 2026
Robert LeBoyer Noble Financial	Noble Financial	Buy Reiterates $50	Buy	Reiterates	$50	+1,292.76%	Aug 13, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

1.37M

Revenue Next Year

149.50M

from 1.37M

10,812.60%

from 1.37M

EPS This Year

-1.27

from -1.67

EPS Next Year

1.69

from -1.27

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	951.00K	675.00K	-	-	1.37M
Gross Profit	-	951.00K	675.00K	-	-	1.30M
Gross Margin	-	100.00%	100.00%	-	-	95.00%
Operating Income	-8.98M	-18.05M	-20.77M	-32.12M	-29.52M	-38.03M
Net Income	-10.02M	-18.06M	-30.54M	-36.73M	-26.56M	-35.38M
EPS	-	-	-	-	-1.67	-1.27
Free Cash Flow	-	-	-	-	-31.34M	-32.60M
No. Analysts	-	-	-	-	-	10

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	10.4M
Avg	1.4M
Low	n/a

Revenue Growth

Chart

Revenue Growth	2027	2028
High	22,320.8%
Avg	10,812.6%
Low	1,903.8%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-0.62
Avg	-1.27
Low	-1.61

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-